Advisory Panel of Experts Endorses F.D.A. Approval of New Alzheimer’s Drug The New York TimesFDA panel backs Eli Lilly’s Alzheimer’s drug The HillOpinion | An Alzheimer’s Advance, Not a Cure-All The Wall Street JournalFDA advisors recommend Eli Lilly’s Alzheimer’s drug donanemab, paving way for approval CNBCAlzheimer’s drug from Eli Lilly wins backing of FDA committee The Washington Post